Komal Jhaveri, Medical Oncologist and Clinical Researcher of Breast Medicine and Early Drug Developments, Section Head of Endocrine Therapy, Breast Medicine Service, and Clinical Director of Early Drug Development Service at Memorial Sloan Kettering Cancer Center, shared A post by Annals of Oncology on X, adding
”Super timely as FDA approved Dato in 1L metastatic TNBC for those who are not PD-1/PDL-1 I candidates based on the phase 3 TB-02 trial today!”
Quoting Annals of Oncology’s post:
”Article in press: Dato-DXd combo with durvalumab as 1L treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from the phase Ib/II BEGONIA study.”
Title: Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study
Authors: P. Schmid, H.-C. Wang, F. Lynce, J. Asselah, K. H. Jung, C. X. Ma, Y. H. Park, S.-C. Chen, P. J. Wysocki, R. D. Baird, Z. Nowecki, R. Fernandes, J. O’Shaughnessy, S. Lord, M.-F. Hou, L.-M. Tseng, C. Prady, P. Rao-Melacini, R. Stewart, K. Warzyszyńska, P. Vuković, S.-A. Im
Other Articles Featuring Komal Jhaveri and Annals of Oncology on OncoDaily.